Beyond Weight Loss: What GLP-1 Research Means for the Future of Medicine

GLP-1 medications, like Ozempic® and Wegovy®, have become one of the biggest topics in health today. Many people know them as weight-loss drugs, but their story is much bigger than weight alone. These medications are changing how doctors think about conditions like diabetes, heart health, and metabolism. They are also helping researchers learn more about how the body controls hunger, blood sugar, and overall health.

So what does this mean for people who are not trying to lose weight?

The answer starts with understanding what GLP-1 medications actually do. GLP-1 stands for glucagon-like peptide-1, a hormone naturally made in the body. This hormone does a few key things:

1. It helps control blood sugar
2. It impacts hunger signals
3. It plays a role in how the body uses energy

GLP-1 medications work by copying some of these natural signals.

GLP-1s and Health

For people with certain health conditions, these medications may help the body manage blood sugar levels, support heart health, and improve other areas of metabolic health. While some people take GLP-1 medications for weight management, the research behind them is exploring many other possible uses.

One important area of research is diabetes care. Some GLP-1 medications were first developed to help people with type 2 diabetes better control their blood sugar. Over time, researchers discovered that these medicines may have effects beyond blood sugar. Studies are continuing to explore how they may impact the heart, kidneys, inflammation, and other parts of the body.

This matters because many health conditions are connected. Heart health, blood sugar, weight, and metabolism often influence each other. A change in one area of health can affect many others.

GLP-1 and The Future

GLP-1 research is also opening the door to new questions. Could they be used in different ways in the future? Could they help treat conditions beyond diabetes and weight management?

Researchers are studying these questions through clinical trials. Clinical research helps doctors understand how new treatments work, who they may help, and what risks or side effects should be considered. Every medical advancement we have today started with people participating in research studies.

Clinical research is currently underway to answer many questions about GLP-1s beyond weight loss:

Can GLP-1 medications help reduce alcohol cravings?

Researchers are studying semaglutide (Ozempic®, Wegovy®) as a possible treatment for alcohol use disorder. In Phase 2 clinical trials, researchers are investigating whether semaglutide affects the brain's reward pathways and helps reduce alcohol cravings and heavy drinking. Early findings are encouraging, but larger studies are needed before the medication could be approved for this use.²

Can GLP-1 medications treat fatty liver disease?

Researchers have been studying semaglutide and tirzepatide (better known as Zepbound®, and Mounjaro®) for metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of fatty liver disease. Semaglutide has shown benefits in late-stage clinical research and is now approved in the United States for certain patients with MASH. Tirzepatide continues to be studied in Phase 2 and Phase 3 clinical trials to determine whether it can reduce liver inflammation and scarring.³

Can GLP-1 medications lower the risk of heart disease?

Researchers studied semaglutide in a large Phase 3 trial, which included adults who are overweight or obese and have established cardiovascular disease. The study found that semaglutide reduced the risk of heart attack, stroke, and cardiovascular death.⁸

Can GLP-1 medications protect the kidneys?

Researchers are evaluating whether semaglutide has shown kidney benefits in people with type 2 diabetes and chronic kidney disease, while tirzepatide is being studied in additional kidney disease trials. Researchers are investigating whether these medications can help slow kidney damage, reduce protein loss in the urine, and delay the need for dialysis.⁴

Can GLP-1 medications improve sleep apnea?

Researchers studied tirzepatide in Phase 3 trials and learned that many participants experienced meaningful improvements in obstructive sleep apnea, including fewer breathing interruptions during sleep. These results led to FDA approval for adults with obesity and moderate-to-severe obstructive sleep apnea. Researchers continue studying the medication's long-term effects on sleep health.⁵

Can people lose weight without losing muscle?

Researchers are studying semaglutide and tirzepatide to better understand changes in body composition during weight loss. Current studies are evaluating how much weight loss comes from body fat versus lean muscle and whether exercise, higher protein intake, or additional therapies can help preserve muscle mass, especially in older adults.⁷

Can next-generation GLP-1 medications work even better?

Researchers are studying retatrutide, an investigational medication that targets three hormones (GLP-1, GIP, and glucagon) instead of one or two. Retatrutide is currently in multiple Phase 3 clinical trials evaluating obesity, cardiovascular disease, kidney disease, osteoarthritis, and other obesity-related conditions. Researchers hope this next generation of medicines may produce more weight loss and additional health benefits.⁸

While they are already changing care for some people, researchers are continuing to learn how these treatments may support health in new ways.

For anyone interested in their health, the biggest takeaway is this: GLP-1 medications are not only about weight loss. They represent a growing area of medicine focused on understanding the body, improving treatments, and finding new ways to support healthier lives.

As research continues, today’s discoveries may help shape the future of healthcare for generations to come.